<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3097">
  <stage>Registered</stage>
  <submitdate>3/03/2011</submitdate>
  <approvaldate>3/03/2011</approvaldate>
  <nctid>NCT01309555</nctid>
  <trial_identification>
    <studytitle>To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod in Australia</studytitle>
    <scientifictitle>Easypod Connect: An Australian Multi-centre, Observational Registry to Study Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using Easypod Electromechanical Device for Growth Hormone Treatment</scientifictitle>
    <utrn />
    <trialacronym>ECOS AUS</trialacronym>
    <secondaryid>EMR 200104-521</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Growth Disorders</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other endocrine disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - easypod

Treatment: devices: easypod
Saizen (Somatropin) as per Summary of Product Characteristics administered by easypod

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Mean percent of adherence by subject</outcome>
      <timepoint>At least 6 months and up to 5 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Correlation of adherence and growth outcome after each year of SAIZEN® treatment with easypod - Correlation of adherence and growth outcome (height velocity (HV), height velocity-standard deviation score (HV-SDS), height, change in height (height SDS) after each year of SAIZEN® treatment with easypod</outcome>
      <timepoint>At least 6 months and up to 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Subject adherence profile based on age, gender, indication, self-injection or not, time on treatment with easypod</outcome>
      <timepoint>At least 6 months and up to 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Correlation of adherence with current IGF-I status (i.e. above, below or within normal ranges)</outcome>
      <timepoint>At least 6 months and up to 5 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Administered growth hormone via the easypod electromechanical device according to the
             SAIZEN® Product Information

          -  Aged between 2 and 18 years

          -  Appropriate Informed Consent/Assent provided</inclusivecriteria>
    <inclusiveminage>2</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>18</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Subjects with mature bone age taking growth hormone (i.e. for taking growth hormone
             for its metabolic effects)

          -  Contra-indications to SAIZEN® as defined in SAIZEN® Product Information

          -  Use of an investigational drug or participation in another interventional clinical
             trial</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>33</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>For Recruiting Locations in Australia - please contact the Merck KGaA Communication Center</hospital>
    <postcode> - please contact the Merck KGaA Communication Center</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Merck KGaA</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Merck Serono Australia Pty Ltd</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is an Australian, Multicentre, Observational Registry to study Adherence and Long Term
      Outcomes of Therapy in paediatric subjects using easypod electromechanical device for growth
      hormone treatment to assess the level of adherence of subject receiving SAIZEN® via easypod.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01309555</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Medical Responsible</name>
      <address>Merck Serono Australia Pty Ltd</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>